Presentation is loading. Please wait.

Presentation is loading. Please wait.

Aminosalicylates in IBD: New Data on an Old Therapy Joel R. Rosh, MD Director, Pediatric Gastroenterology Goryeb Children’s Hospital/Atlantic Health Professor.

Published byJayson McKinney Modified over 9 years ago

Similar presentations

Presentation on theme: "Aminosalicylates in IBD: New Data on an Old Therapy Joel R. Rosh, MD Director, Pediatric Gastroenterology Goryeb Children’s Hospital/Atlantic Health Professor."— Presentation transcript:

1 Aminosalicylates in IBD: New Data on an Old Therapy Joel R. Rosh, MD Director, Pediatric Gastroenterology Goryeb Children’s Hospital/Atlantic Health Professor of Pediatrics Icahn School of Medicine, Mount Sinai School of Medicine

2 Disclosures Grant Support: – Abbvie, Astra-Zeneca, Janssen Consultant: – Abbvie, Given, Janssen, Soligenix Honoraria/Speakers’ Bureau – Abbott Nutrition, Abbvie, Prometheus

3 Adapted from Qureshi AI et al. Adv Drug Deliv Rev. 2005;57:281-302 Mesalamine: Clinical Pharmacology 5-HETE = 5-hydroxyeicosatetraenoic acid; PG = prostaglandin; TX = thromboxane.

4 AMINOSALICYLATE DISTRIBUTION

5 Approved Drugs for IBD AgentAdult Approval Pediatric Approval Infliximab CD + UC Yes Adalimumab UC YesNo Adalimumab CD Yes Certolizumab Pegol CD YesNo Golimumab UC YesNo Vedolizumab CD YesNo NatalizumabYesNo AZANo 6MPNo MTXNo * Grandfathered in, minimal data AgentAdult Approval Pediatric Approval AzulfidineYes“Yes”* PentasaYesNo AsacolYesNo Asacol HD YesNo LialdaYesNo AprisoYesNo CanasaYesNo ColazalYes Pred“Yes”

6 Current Therapy for Newly Diagnosed Children with Crohn’s Disease (N=1271)* TherapyBy Q1By Q2By Q4By Q8By Q12 Corticosteroids 927 (76%)943 (78%)968 (83%)1008 (89%) 1022 (93%) 6MP/Aza 634 (53%)728 (63%)807 (72%)854 (81%) 880 (89%) Methotrexate 71 (6%)103 (9%)141 (14%)199 (24%) 225 (36%) 5-ASA/SASP 783 (64%)821 (68%)849 (72%)870 (79%) 871 (86%) Infliximab 145 (11%)202 (16%)281 (22%)395 (31%) 449 (35%) Adalimumab 2 (0.2%)9 (1%)18 (2%)41 (5%)63 (12%) Enteral Nutrition 72 (6%)77 (7%)83 (8%)96 (12%)100 (18%) Antibiotics 388 (33%)435 (38%)491 (46%)559 (58%) 589 (71%) *Pediatric IBD Collaborative Research Group Registry, Unpublished data 2012 Slide Courtesy of Jeff Hyams

7 Current Therapy for Newly Diagnosed Children with Crohn’s Disease (N=1271)* TherapyBy Q1By Q2By Q4By Q8By Q12 Corticosteroids 927 (76%)943 (78%)968 (83%)1008 (89%) 1022 (93%) 6MP/Aza 634 (53%)728 (63%)807 (72%)854 (81%) 880 (89%) Methotrexate 71 (6%)103 (9%)141 (14%)199 (24%) 225 (36%) 5-ASA/SASP 783 (64%)821 (68%) 849 (72%) 870 (79%) 871 (86%) Infliximab 145 (11%)202 (16%)281 (22%)395 (31%) 449 (35%) Adalimumab 2 (0.2%)9 (1%)18 (2%)41 (5%)63 (12%) Enteral Nutrition 72 (6%)77 (7%)83 (8%)96 (12%)100 (18%) Antibiotics 388 (33%)435 (38%)491 (46%)559 (58%) 589 (71%) *Pediatric IBD Collaborative Research Group Registry, Unpublished data 2012 Slide Courtesy of Jeff Hyams

8 Risk Difference 95% CI -0.5-0.4-0.3-0.2-0.110.10.20.30.40.5 Mesalamine for Maintenance of Medically Induced Remission in Crohn’s Disease Favors TreatmentFavors Control Group 1995 Arber 1997 De Franchis 1997 Sutherland 1996 Modigliani 1995 Thomson 1994 Bresci 1993 Gendre 1992 Brignola 1992 Prantera 1990 Thomson DateStudy Overall Studies n=1371 Camma et al, Gastroenterology 2000; 119:597

9 5ASA Maintenance in Pediatric CD: Placebo Controlled RCT N = 122

10 Current Therapy for Newly Diagnosed Children with Ulcerative Colitis (N=486)* TherapyBy Q1By Q2By Q4By Q8By Q12 Corticosteroids 348 (75%)358 (78%)379 (83%)387 (90%)391 (94%) 6MP/Aza 110 (25%)152 (35%)197 (49%)228 (64%)234 (75%) Methotrexate 0 (0.0%)2 (0.5%)5 (1%)14 (5%)16 (8%) 5-ASA/SASP 417 (87%)426 (89%)437 (92%)442 (94%)445 (96%) Infliximab 27 (6%)42 (9%)69 (14%)93 (19%)100 (21%) Adalimumab 1 (0.2%) 4 (1%)6 (2%)6 (3%) *Pediatric IBD Collaborative Research Group Registry, Unpublished data 2012 Slide Courtesy of Jeff Hyams

11 Current Therapy for Newly Diagnosed Children with Ulcerative Colitis (N=486)* TherapyBy Q1By Q2By Q4By Q8By Q12 Corticosteroids 348 (75%)358 (78%)379 (83%)387 (90%)391 (94%) 6MP/Aza 110 (25%)152 (35%)197 (49%)228 (64%)234 (75%) Methotrexate 0 (0.0%)2 (0.5%)5 (1%)14 (5%)16 (8%) 5-ASA/SASP 417 (87%)426 (89%) 437 (92%) 442 (94%) 445 (96%) Infliximab 27 (6%)42 (9%)69 (14%)93 (19%)100 (21%) Adalimumab 1 (0.2%) 4 (1%)6 (2%)6 (3%) *Pediatric IBD Collaborative Research Group Registry, Unpublished data 2012 Slide Courtesy of Jeff Hyams

12 Outcome of 5 ASA Therapy: Newly Diagnosed Pediatric UC Zeisler B, et al. JPGN 2013;56:12-18

13 Outcome of 5 ASA Therapy: Newly Diagnosed Pediatric UC Zeisler B, et al. JPGN 2013;56:12-18

14 Outcome of 5 ASA Therapy: Newly Diagnosed Pediatric UC Zeisler B, et al. JPGN 2013;56:12-18 Only 33% were offered rectal therapy by one year

15 Treatment of Distal UC: Oral and Rectal Mesalamine Therapy Safdi M et al. Am J Gastroenterol. 1997;92:1867. 1 Week2 Weeks3 Weeks6 Weeks * * * 0 Patients Reporting No Rectal Bleeding (%) 100 50 75 25 Oral (2.4 g/d) Rectal (4 g/d) Combined *P<.05 vs oral alone Slide Courtesy of the GI Health Foundation

16 Dose of Oral 5-ASA Not Important For Maintenance of Remission in UC Cochrane Database of Systematic Reviews 17 OCT 2012 DOI: 10.1002/14651858.CD000544.pub3 http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD000544.pub3/full#CD000544-fig-00501 http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD000544.pub3/full#CD000544-fig-00501

17 5-ASA Content of 5-ASA Preparations GenericTrade5-ASA Content (%) Usual DosageAmount of 5- ASA Delivered SulfasalazineAzulfidine, Azulfidine EN, Sulfazine, Sulfazine EC 384 g1.6 g MesalamineApriso, Asacol HD, Canasa, Delzicol, Lialda, Pentasa, Rowasa, SfRowasa, 1002.4-4.8 g BalsalazideColazal, Giazo353.3-6.75 g1.2 g-2.4 g OlsalazineDipentum1001 g Adapted from: Ulcerative Colitis-The Complete Guide to Medical Management (Lichtenstein)

18 Efficacy of Once vs. Twice Daily 5-ASA for Induction of Remission in UC Lichtenstein GR, et al. Clin Gastroenterol Hepatol. 2007;5:95–102

19 Adherence: 5-ASA Persistency at12 Months Kane S. Dig Dis Sci. 2011;56:3463. Slide Courtesy of the GI Health Foundation

20 Importance of Adherence Kane et al, Am J Med 2003; 114:39-43 0 25 50 75 100 Percentage of Patients (%) Remaining in Remission 403632Adherent n = Nonadherent n =593228 Adherent Nonadherent 01224Time (months)36 Adherent patients have an 89% chance of maintaining remission compared with only 39% for nonadherent patients (P = 0.001)

21 Crohn’s and Colitis Foundation of America Survey: Primary Reasons for Nonadherence % of Respondents Crohn’s and Colitis Foundation of America [press release]. Available at: http://www.ccfa.org/about/press/uccompliance. Accessed April 27, 2007. N=944 nonadherent patients; some questions within the survey allowed more than 1 response per respondent. 90% of nonadherent patients “just forgot” to take their medication N = 1595

22 Slide courtesy of Neal LeLeiko Medical Event Monitoring System: MEMS Cap

23 5-ASA and 6-MP Adherence by MEMS Cap COHORT I NEWLY DX COHORT II PREVIOUSLY DX FSIG(total adherence) 5-ASA 6-MP LeLeiko N, et al. Inflamm Bowel Dis. 2013;19:832-839

24 5-ASA and 6-MP Adherence by MEMS Cap COHORT I NEWLY DX COHORT II PREVIOUSLY DX FSIG(total adherence) 5-ASA59.9546.232.32.1353% 6-MP43.2560.732.26.1448% LeLeiko N, et al. Inflamm Bowel Dis. 2013;19:832-839

25 Conclusions 5ASA is commonly used by Peds GI community Evidence for efficacy in CD very limited – ?correct phenotype (colonic + careful monitoring) 40% steroid free remission at 1 year in UC – Role of adherence – ?does dose matter – ? Role for greater use of rectal administration

26 Conclusions 5ASA is commonly used by Peds GI community Evidence for efficacy in CD very limited – ?correct phenotype (colonic + careful monitoring) 40% steroid free remission at 1 year in UC – Role of adherence – ?does dose matter – ? Role for larger uptake of rectal route

Download ppt "Aminosalicylates in IBD: New Data on an Old Therapy Joel R. Rosh, MD Director, Pediatric Gastroenterology Goryeb Children’s Hospital/Atlantic Health Professor."

Similar presentations

Who should receive early anti-TNF therapy: With what benefits and risks? Ted Denson, MD Cincinnati Childrens Hospital Medical Center University of Cincinnati.

Who should receive early anti-TNF therapy: With what benefits and risks? Ted Denson, MD Cincinnati Childrens Hospital Medical Center University of Cincinnati.
Methotrexate Indications and Approaches

Methotrexate Indications and Approaches
Monotherapy using 6-MP or azathioprine for Crohn’s disease is dead: out with the old and in with the new Stephen B. Hanauer, MD Professor of Medicine Clinical.

Monotherapy using 6-MP or azathioprine for Crohn’s disease is dead: out with the old and in with the new Stephen B. Hanauer, MD Professor of Medicine Clinical.
Miguel Regueiro, M.D. Professor of Medicine

Miguel Regueiro, M.D. Professor of Medicine
Immunomodulators and Biologics Maria T. Abreu, MD University of Miami Miller School of Medicine Miami, Florida.

Immunomodulators and Biologics Maria T. Abreu, MD University of Miami Miller School of Medicine Miami, Florida.
………………..…………………………………………………………………………………………………………………………………….. Jennifer L. Dotson, MD, MPH Assistant Professor of Pediatrics Division of Gastroenterology,

………………..…………………………………………………………………………………………………………………………………….. Jennifer L. Dotson, MD, MPH Assistant Professor of Pediatrics Division of Gastroenterology,
Journal Club: Biologic Agents in UC, Systematic Review and Network Meta-analysis, by Danese et al., Annals 2014 Barrett G. Levesque, MD Assistant Professor.

Journal Club: Biologic Agents in UC, Systematic Review and Network Meta-analysis, by Danese et al., Annals 2014 Barrett G. Levesque, MD Assistant Professor.
Colitis in the Very Young

Colitis in the Very Young
Management of Inflammatory bowel disease 8/12/10.

Management of Inflammatory bowel disease 8/12/10.
Thiopurines have no role in the management of Pediatric IBD Robert N. Baldassano, MD Colman Professor of Pediatrics University of Pennsylvania, Perelman.

Thiopurines have no role in the management of Pediatric IBD Robert N. Baldassano, MD Colman Professor of Pediatrics University of Pennsylvania, Perelman.
Adherence Issues in IBD Sunanda Kane MD MSPH Professor of Medicine Mayo Clinic Rochester.

Adherence Issues in IBD Sunanda Kane MD MSPH Professor of Medicine Mayo Clinic Rochester.
Thiopurines still have a role in the management of pediatric IBD Athos Bousvaros MD, MPH Associate Director, IBD program Boston Children’s Hospital.

Thiopurines still have a role in the management of pediatric IBD Athos Bousvaros MD, MPH Associate Director, IBD program Boston Children’s Hospital.
Emerging treatments in Crohn’s disease and ulcerative colitis

Emerging treatments in Crohn’s disease and ulcerative colitis
End points in IBD treatment Mucosal healing Vs Symptom relief Jose Francis Lakeshore Hospital Kochi.

End points in IBD treatment Mucosal healing Vs Symptom relief Jose Francis Lakeshore Hospital Kochi.
6-MP and AZA Applications and Approaches

6-MP and AZA Applications and Approaches
Therapy of Inflammatory Bowel Diseases 2013 Gastroenterology Department Division of Medicine Eran Israeli MD.

Therapy of Inflammatory Bowel Diseases 2013 Gastroenterology Department Division of Medicine Eran Israeli MD.
The Patient With Pyoderma Gangrenosum Maria T. Abreu, MD Chief, Division of Gastroenterology University of Miami Miller School of Medicine Miami, Florida.

The Patient With Pyoderma Gangrenosum Maria T. Abreu, MD Chief, Division of Gastroenterology University of Miami Miller School of Medicine Miami, Florida.
Ghassan Wahbeh MD Associate Professor, Director IBD Program Seattle Children’s Hospital University of Washington.

Ghassan Wahbeh MD Associate Professor, Director IBD Program Seattle Children’s Hospital University of Washington.
When can we use combination therapy for our pediatric IBD patients? Athos Bousvaros MD, MPH Advances in IBD Dec 2014.

When can we use combination therapy for our pediatric IBD patients? Athos Bousvaros MD, MPH Advances in IBD Dec 2014.
Progress in Diagnosing and Treating Clostridium difficile in IBD patients Alan C. Moss MD, FEBG, FACG, AGAF Associate Professor of Medicine Director of.

Progress in Diagnosing and Treating Clostridium difficile in IBD patients Alan C. Moss MD, FEBG, FACG, AGAF Associate Professor of Medicine Director of.

Similar presentations

Ads by Google